Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
C.R. Bard
MedTech
ACC: Study finds no increased death risk with paclitaxel devices
An audit of nearly four years of Medicare data spanning more than 168,000 beneficiaries found no evidence of additional harm.
Conor Hale
May 16, 2021 5:30pm
Stryker makes offer to take over Boston Scientific, report says
Jun 12, 2018 1:55pm
FDA OKs Bard’s Lutonix drug-coated balloon for renal disease complication
Aug 28, 2017 12:14pm
Trade watchdog demands more information from BD, Bard
Jun 12, 2017 9:59am
BD pens $24B Bard buyout to create medtech powerhouse
Apr 24, 2017 3:12am